1997
Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective, Open-Label Study
MCDOUGLE C, HOLMES J, BRONSON M, ANDERSON G, VOLKMAR F, PRICE L, COHEN D. Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal Of The American Academy Of Child & Adolescent Psychiatry 1997, 36: 685-693. PMID: 9136504, DOI: 10.1097/00004583-199705000-00020.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderDevelopmental disordersRisperidone treatmentClinical Global Impression ScaleOpen-label studyOpen-label trialPlacebo-controlled studyCommon side effectsEfficacy of risperidoneShort-term safetyGlobal Impression ScaleGlobal improvement itemBehavioral ratingsChildhood disintegrative disorderSocial relatednessTreatment of childrenAsperger's disorderRepetitive behaviorsAutistic disorderBehavioral symptomsBaseline visitMean ageImpression ScaleAdolescentsOptimal dose
1996
Parental Presence during Induction of Anesthesia
Kain Z, Mayes L, Caramico L, Silver D, Spieker M, Nygren M, Anderson G, Rimar S. Parental Presence during Induction of Anesthesia. Anesthesiology 1996, 84: 1060-1067. PMID: 8623999, DOI: 10.1097/00000542-199605000-00007.Peer-Reviewed Original ResearchConceptsInduction of anesthesiaSerum cortisol concentrationsLow baseline levelsParental presencePhysiologic measuresBaseline levelsCortisol concentrationsPreoperative behavioral interventionsMultivariate linear regression analysisOutpatient surgeryIntervention groupLinear regression analysisControl groupParent-absent groupBaseline temperamentAnesthesiaBehavioral interventionsChild's ageSignificant differencesChildrenRegression analysisInterventionLow trait anxietyTrait anxietyAnxiety
1994
Aspartame, behavior, and cognitive function in children with attention deficit disorder.
Shaywitz B, Sullivan C, Anderson G, Gillespie S, Sullivan B, Shaywitz S. Aspartame, behavior, and cognitive function in children with attention deficit disorder. Pediatrics 1994, 93: 70-5. PMID: 7505423, DOI: 10.1542/peds.93.1.70.Peer-Reviewed Original ResearchConceptsAttention deficit disorderWisconsin Card Sorting TestDeficit disorderTreatment Emergent Symptom ScalePlacebo-controlled crossover studyComplete blood cell countStudy centersLiver function testsUrinary excretion rateBlood cell countAdministration of aspartameMental Disorders criteriaCognitive testsMeasurement of catecholaminesCrossover studyFunction testsMonoamine metabolismInpatient admissionsMetabolite excretionLarge dosesSymptom ScaleUsual consumptionCell countPlasma phenylalanineBiochemical measures
1990
Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder
Shaywitz B, Shaywitz S, Sebrechts M, Anderson G, Cohen D, Jatlow P, Young J. Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder. Life Sciences 1990, 46: 625-633. PMID: 2308471, DOI: 10.1016/0024-3205(90)90131-a.Peer-Reviewed Original Research
1986
Components of attention, methylphenidate dosage, and blood levels in children with attention deficit disorder.
Sebrechts M, Shaywitz S, Shaywitz B, Jatlow P, Anderson G, Cohen D. Components of attention, methylphenidate dosage, and blood levels in children with attention deficit disorder. Pediatrics 1986, 77: 222-8. PMID: 3945535, DOI: 10.1542/peds.77.2.222.Peer-Reviewed Original ResearchConceptsAttention deficit disorderDeficit disorderComponents of attentionDoses of methylphenidateCognitive resourcesCognitive componentsAttentional deficitsParent ratingsMethylphenidate dosageTest batteryMethylphenidateChildrenDisordersTaskDeficitsRatingsSingle testAttentionPerformanceTeachersBlood levelsBatteries